RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
暂无分享,去创建一个
G. Salles | G. Fingerle-Rowson | P. Zinzani | M. Winderlich | B. Feinberg | S. Ambarkhane | G. Nowakowski | A. Barbui | Thomas D. Rodgers | S. Tillmanns | N. Fowler | S. Parche | D. Marino | E. Meli | M. Frezzato | C. Castellino | D. Dey | N. Kurukulasuriya | G. Nowakowski
[1] I. Flinn,et al. Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel) , 2020 .
[2] G. Salles,et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. , 2020, The Lancet. Oncology.
[3] D. Margolis,et al. Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies. , 2020, Clinical lymphoma, myeloma & leukemia.
[4] A. Mackensen,et al. Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide , 2019, Blood.
[5] L. Sehn,et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Dombret,et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia , 2019, Cancer.
[7] S. Barta,et al. Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment , 2019, American journal of hematology.
[8] P. Zinzani,et al. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. , 2019, The oncologist.
[9] G. Salles,et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.
[10] C. Buske,et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J. Cerhan,et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.
[12] J. Cerhan,et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front‐line immunochemotherapy , 2017, British journal of haematology.
[13] L. Staudt,et al. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2017, Clinical Cancer Research.
[14] B. Coiffier,et al. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? , 2016, Hematology. American Society of Hematology. Education Program.
[15] J. Gribben,et al. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Rossi,et al. Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival , 2014, PloS one.
[17] Michael L. Wang,et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial , 2013, Leukemia.
[18] J. Vose,et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] P. Austin. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.
[20] David Jarjoura,et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. , 2010, Blood.
[21] I. Lossos,et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Holly M Horton,et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. , 2008, Cancer research.
[23] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Zelenetz,et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.
[25] A. Zelenetz,et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. , 2003, Blood.
[26] L. Tanoue,et al. The National Comprehensive Cancer Network , 1998, Cancer.
[27] J. Patterson. Lymphomas. , 1992, Dermatologic clinics.